Meeting
2017 ASCO Annual Meeting
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.
Authors
Hirotsugu Kenmotsu
Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
Hirotsugu Kenmotsu , Fumikazu Sakai , Terufumi Kato , Masahiko Kusumoto , Tomohisa Baba , Kazuyoshi Kuwano , Akihiko Gemma , Kazuhiko Nakagawa , Yoichi Nakanishi , Nobuyuki Yamamoto , Yoshihiko Ito , Yasuhiro Tahara , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9078)
DOI
10.1200/JCO.2017.35.15_suppl.9078
Abstract #
9078
Poster Bd #
404
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors for fatal outcome.
First Author: Terufumi Kato
Poster
2015 ASCO Annual Meeting
Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC).
First Author: Makoto Nishio
Poster
2022 ASCO Annual Meeting
Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non–small lung cancer.
First Author: Wakako Daido
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang